Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics

Spencer B. Mamer, Si Chen, Jared C. Weddell, Alexandra Palasz, Ashley Wittenkeller, Manu Kumar & P. I. Imoukhuede

Nearly all studies of angiogenesis have focused on uni-family ligand-receptor binding, e.g., VEGFs bind to VEGF receptors, PDGFs bind to PDGF receptors, etc. The discovery of VEGF-PDGFRs binding challenges this paradigm and calls for investigation of other ligand-receptor binding possibilities. We utilized surface plasmon resonance to identify and measure PDGF-to-VEGFR binding rates, establishing cut-offs for binding and non-binding interactions. We quantified the kinetics of the recent VEGF-A:PDGFRβ interaction for the first time with $K_D = 340$ pM. We discovered new PDGF:VEGFR2 interactions with PDGF-AA:R2 $K_D = 530$ nM, PDGF-AB:R2 $K_D = 110$ pM, PDGF-BB:R2 $K_D = 40$ nM, and PDGF-CC:R2 $K_D = 70$ pM. We computationally predict that cross-family PDGF binding could contribute up to 96% of VEGFR2 ligation in healthy conditions and in cancer. Together the identification, quantification, and simulation of these novel cross-family interactions posits new mechanisms for understanding anti-angiogenic drug resistance and presents an expanded role of growth factor signaling with significance in health and disease.

The vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR) signaling family has been extensively studied because it is the major regulator of microvascularization. VEGF-targeted monoclonal antibodies have been developed to inhibit microvascular growth; and VEGF has also been applied to promote vascularization in engineered grafts, bioreactors, and tissue. However, anti-angiogenic approaches have not yielded the promise of sustained vascular inhibition nor have pro-angiogenic approaches yielded stable blood vessel growth. This is likely due to the fact that angiogenesis involves several signaling pathways, in addition to VEGF, representing a cross-family signaling complexity that cannot be captured by targeting one growth factor alone.

Increasing evidence suggests that a cross-family view of cell signaling offers promise in controlling angiogenesis. For example, VEGF-inhibition eventually results in anti-angiogenic resistance and one resistance mechanism involves the upregulation of ancillary axes, including: platelet derived growth factors (PDGFs), fibroblast growth factor, and angiopoietins. Moreover, incorporating a cross-family view of angiogenesis into therapeutics has led to synergistic effects and improved blood flow, when dual-growth factor therapy is applied in pre-clinical ischemia models, and improved wound healing, when dual-growth factors are coupled to biomaterials for tissue-engineering. Together, these cross-family compensatory mechanisms and therapeutic advances suggest a need to shift from examining the VEGF-family alone toward directed exploration of combined growth factor signaling pathways—a cross-family paradigm.

The canonical angiogenesis philosophy involves uni-family ligand-receptor binding: VEGFs bind to VEGFRs, PDGFs bind to PDGFRs, and so on. This paradigm offers numerous activation schemes. For example, VEGF-A, -B, -C, -D, & placental growth factor and several isoforms produced via alternative splicing bind to selected VEGFRs: VEGFR1, -2, and -3 co-receptors: neuropilin-1 and neuropilin-2 leading to the angiogenic hallmarks of endothelial cell proliferation and migration to hypoxic regions. PDGFs also contribute to vascular function. PDGF-AA, -BB, -AB, -CC, and -DD binding to corresponding PDGFRs (α and β) maintains and stabilizes endothelial tubes during development, promotes endothelial cell proliferation and regeneration, and induces reperfusion after arterial blockage. (A full schematic detailing the selective binding between these ligands and receptors is shown in Fig. 1).

Since VEGFs and PDGFs are both key regulators of angiogenesis, shifting the focus of angiogenesis away from a uni-family (VEGF-family alone) and towards a dual-family (VEGF and PDGF) focus would be a

Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA. Correspondence and requests for materials should be addressed to P.I.I. (email: pili@illinois.edu)
practical approach in exploring a cross-family angiogenesis framework. Indeed, one study of dose-dependent VEGF-A:PDGFR activation has provided an example of this new signaling paradigm. They found that VEGF-A directly binds both PDGF receptors and induce their phosphorylation in a dose-dependent fashion. However, additional cross-family interactions, such as PDGFs to VEGFRs and other VEGFs (VEGF-B, -C, and -D) to PDGFRs, remain unexplored.

There are several, compelling reasons why additional cross-family signaling interactions may occur. Structurally, PDGF and VEGF are similar, hailing from the cysteine knot superfamily. The dimeric form of VEGF and PDGF shows significant alignment with a 1.8 Å root mean square difference, despite the low VEGF—PDGF sequence homology (<20%). Furthermore, recent experimental studies established that VEGFR2 and PDGFRβ can form complexes on pericytes, the mural cells that mediate vessel stability. Therefore, measurement of possible cross-family interactions could reveal new angiogenic mechanisms.

Here we identify, measure, and simulate binding across the VEGF and PDGF families. We establish new standards for identifying and measuring new protein-protein interaction kinetics. We predict the significance of these cross-family binding interactions via computational modeling and present evidence that these novel interactions should significantly modulate angiogenic signaling, particularly in cancer. Overall, these cross-family interactions offer a shifted paradigm for understanding cell signaling with implications to angiogenesis, health, and disease.

Results

Validation of SPR protocol. We measured the kinetic rate constants between PDGF ligands and VEGF receptors using a surface plasmon resonance (SPR) assay. We injected the ligands at 40, 20 and 10 nM (process summarized in Fig. 2) and fit their association and dissociation curves using a 1:1 Langmuir binding model. To measure the accuracy of our kinetic analyses we applied a $\chi^2$-to-$R_{\text{max}}$ ratio heuristic. For known interactions, a $\chi^2$-to-$R_{\text{max}}$ value < 0.20, represents a well-established filter for high-quality fitting of kinetic parameters obtained via SPR. The $\chi^2$-to-$R_{\text{max}}$ ratio can be helpful in detecting new 1:1 binding interactions, because this value describes how well the obtained sensogram curves fit a 1:1 Langmuir interaction model. When the fitting noise
(χ²) exceeds the maximal response (R_max), the interaction cannot be said to follow the binding model. We therefore introduce a heuristic where a χ²-to-R_max ratio ≤ 1.0 is attributed to "true" interactions, and those >1.0 are described as non-1:1 Langmuir interactions resulting from non-specific binding.

To validate the χ²-to-R_max cut-off approach, we examined ligand:receptor pairs known to bind and non-interactions (i.e. pairs known not to bind). The χ²-to-R_max cut-off approach correctly identified well-established VEGF:VEGFR and PDGF:PDGFR ligand:receptor pairs as real interactions (χ²-to-R_max < 1.0), and accurately excluded those known to not interact (χ²-to-R_max > 1.0). Specifically, VEGF-A:VEGFR1 and VEGFR2, PDGF-AA:PDGFRs, PDGF-AB:PDGFRα, PDGF-BB:PDGFRs, and PDGF-CC:PDGFRs were correctly designated as real interactions, with χ²-to-R_max < 1.0 for each (Supplementary Table S1). The following non-binding pairs were correctly excluded: VEGF-A:VEGFR3, PDGF-AA:PDGFR3, with χ²-to-R_max ratios 6.0- and 8.6-fold larger than the cut-off. The validation of the heuristic across 7 ligand:receptor pairs of the VEGFR and PDGFR families offers strong support for its extension to cross-family interactions within these families (Fig. 1 and Supplementary Table S1).

We further validated our experimental approach by reproducing previously measured binding affinities. The VEGF-A:VEGFR1 and VEGF-A:VEGFR2 binding affinities (Fig. 3A and Supplementary Table S2) were both within an order of magnitude of previous SPR measurements, K_D(VEGF-A:VEGFR1 and VEGFR2) binding affinities (Fig. 3A and Supplementary Table S2) were both within an order of magnitude of previous SPR measurements, K_D = 7.5 pM39, and K_D = 9.8 pM (Fig. 3B) versus a previous measured K_D = 7.5 pM40, and K_D = 9.8 pM (Fig. 3B) versus 52 pM41, respectively.

Establishing kinetic and affinity constants for canonical PDGF:PDGFR interactions. We confirmed that the canonical understanding of PDGF:PDGFR holds (Fig. 1). More specifically, PDGF-AA binds only to PDGFRα (Fig. 4A,B), both PDGFRs bind PDGF-AB (Fig. 4C,D), BB (Fig. 4E,F), and -CC (Fig. 4G,H)42; and PDGF-DD binds only to PDGFR3 (Fig. 4I,J)42. We then compared the obtained affinities, when possible, to previously reported affinities. Currently only PDGF-AA and -BB:PDGFR interactions have been reported via a study that did not use a reference protein cell (Supplementary Table S3). As described in the Materials and Methods, we used to reference protein to measure and account for non-specific binding effects that would affect our kinetics. All binding affinities values are listed exactly in Supplementary Table S2. We measured a PDGF-AA:PDGFRα affinity of the same order of magnitude as previously reported (measured K_D = 660 nM versus prior 134 nM43). We determined that PDGF-BB binds both PDGFRα and PDGFR3 with similar affinities K_D = 420 nM and 830 nM, respectively. While these measured affinities were lower than a previous report (K_D = 150 nM and 1.6 nM for PDGFRα and PDGFR3, respectively) these previous studies did not use a reference protein43. We believe that this difference is critical: without a reference protein, these prior studies measure a weaker binding affinity due to an inflated non-specific binding reference measurement. Furthermore, the relative strength of binding –BB:Rα > –BB:Rβ, is observed in both our study and the work of others.

We also characterized the binding rates and affinities for the canonical PDGF:PDGFR interactions lacking kinetic data (-AB, -CC, -DD:Rα and -AB, -CC, -DD:Rβ). We observed that PDGF-AB:PDGFRα binding affinity was ~2.6x stronger than PDGFRα:PDGFRβ, with affinity constants of K_D = 840 nM versus K_D = 2,200 nM, respectively (Fig. 5A). We measured strong affinities between PDGF-CC:PDGFRα and PDGF-CC:PDGFRβ with K_D = 3.4 nM and 1.9 nM (Fig. 5A). Finally, we observed that PDGF-DD binds PDGFRβ with high affinity, K_D = 67 nM (Fig. 5A). PDGF-DD:PDGFRβ has a 50-fold larger peak association response than its binding to PDGFRα, but its kinetic fitting for this interaction produced a χ²-to-R_max of 2.2 (Supplementary Table S1). But since it is >1.0, it displays high noise to signal, which we interpret as not true 1:1 Langmuir interactions.

Novel cross-family PDGF:VEGFR2 interactions. We identified novel interactions between PDGF-AA, -AB, -BB, and -CC with VEGFR2 (Fig. 6A–D, respectively). These interactions all exhibited classic signal responses, characterized by a steady signal increase upon ligand injection, association-phase, followed by a steady signal decrease during buffer injection, dissociation-phase (Fig. 6). We show examples of this in PDGF:PDGFR binding (Fig. 5), and all were all found to have χ²-to-R_max < 1.0, indicating true 1:1 Langmuir interactions (Supplementary Table S1). There was no evidence of PDGF interactions with VEGFR1 or VEGFR3 (Supplementary Fig. S1). A summary of the novel interactions identified can be found in Fig. 7. When we quantified binding rates (k_a and k_d) and affinity constants (K_D = k_a/k_d), we observed that PDGF-CC:VEGFR2 had an affinity constant of the same order of magnitude as native VEGF-A:VEGFR2 binding with K_D = 3.4 nM.
~70 pM versus (VEGF-A:R2) ~10 pM. The other PDGFs presented VEGFR2 binding affinities with decreasing strength as follows: PDGF-AB > BB > AA. Another notable finding was that PDGF-CC bound VEGFR2 at an affinity greater than or equal its binding to either PDGFR (Fig. 5A). PDGF-AA:VEGFR2 binding was higher affinity, but similar order of magnitude as PDGF-CC:PDGFRβ binding, $K_D$ (-AA:R2) = 100 nM, vs. (-AA:Rβ) = 660 nM. PDGF-AB:VEGFR2 binding was higher affinity than its binding to PDGF-AB:PDGFRs with $K_D$ (-AB:R2) = 110 pM vs. (AB:PDGFRs) > 800 nM. Additionally, PDGF-BB:VEGFR2 binding was higher affinity than its binding to PDGFRs, $K_D$ (-BB:R2) = 37 nM vs. (-BB:PDGFRs) > 400 nM (Fig. 5A). The exact values obtained for binding affinities can be found listed in Supplementary Table S2.

**Association and dissociation rate constants reveal affinity trends.** The affinity of the PDGF-VEGFR2 interaction is best understood by examining both association and dissociation rate constants. Here we observe that the high-VEGF:VEGFR2 affinity is attributed to fast association, $10^8 M^{-1} s^{-1}$ (Fig. 5B), and slow dissociation, $1$ day$^{-1}$ (Fig. 5C.) Only the PDGF-CC:PDGFRβ association
Figure 6. PDGF to VEGFR association and dissociation signal. BIAcore signal response kinetics studies of interactions between (A) PDGFAA and VEGFR2 (B) PDGFAB and VEGFR2 (C) PDGFBB and VEGFR2 and (D) PDGFCC and VEGFR2.

Figure 7. Summary of novel cross-family VEGF and PDGF ligand-receptor interactions. Schematic illustrates an updated view of the VEGF and PDGF ligand-receptor binding patterns, adding newly discovered PDGF-VEGFR interactions. Specifically, only new interactions where the kinetic analysis fit $\chi^2$-to-$R_{\text{max}}$ ratio $< 1.0$ were included. Previously-known interactions are indicated with grey lines, and newly-found interactions are indicated with red lines.
dynamics, which supports its high-affinity binding to PDGFR\(\beta\) (Fig. 5A). All other association dynamics are \(<\sim 10^5 \text{ M}^{-1} \text{s}^{-1}\). The slow VEGF:VEGFR2 dissociation rate constant is exceeded by PDGF-AB:VEGFR2, \(\sim 1/7\) days (i.e. dissociating on average once per week), explaining its \(\sim 100\) pM binding affinity (Fig. 5A). All other dissociation rate constants are “faster”—i.e. higher values—in the range \(1/\text{minutes}\) and \(1/\text{hours}\) (i.e. one molecule dissociates on average per minute and per hour, approximately). (The exact values obtained for association and dissociation rate constants can be found listed in Supplementary Table S2.)

Model construction and validation. To predict the significance of PDGF-VEGFR2 cross-family binding, we derived the ordinary differential equations describing these ligand-receptor interactions based on the law of mass action. Klipp et al. and Linderman & Lauffenburger offer comprehensive explanation of this approach for representing protein-protein interactions. Towards this goal, we simulated two sets of models governing VEGFR ligation: one describing the canonical, uni-family VEGF-A:VEGFR binding and one describing cross-family binding that includes both the canonical uni-family VEGF:VEGFR and our newly derived cross-family PDGF:VEGFR2 binding (PDGF-AA, -AB, & -BB with VEGFR2) (see model schematic Fig. 8). We do not include PDGF-CC in the model because PDGF-CC has not been found to be expressed in humans under healthy or cancer conditions, but is instead observed following a ischemic event like a stroke or myocardial infarction. We recapitulated the benchmark, uni-family VEGF-A:VEGFR model by Mac Gabhann, showing consistent VEGFR1 and VEGFR2 fractional occupancies (Fig. 9A) and maximal responses (Fig. 9B).

We analyzed these two models for ligand concentrations found in healthy physiology, breast cancer, and anti-VEGF-A therapy in breast cancer. Bevacizumab is used as the basis of the anti-VEGF-A treatment, implemented as a binding interaction between bevacizumab and non-receptor-bound VEGF-A. Model equations and parameters are listed in full in Supplementary Files 1 and Supplementary Table S4, respectively.

Localized PDGF cross-family binding enhances VEGFR2 activation in health and cancer. We predict increased VEGFR2 complex formation in every case where PDGF-VEGFR2 cross-family interactions are considered. First, the cross-family model in comparison to the uni-family model predicts a 14-fold increase in VEGFR2 ligation under healthy physiology (Fig. 10A). Similarly, the cross-family model predicts a 15-fold increase in VEGFR2 ligation in breast cancer xenograft-derived endothelial cells over the canonical, uni-family framework (Fig. 10A). Also, we observe that an anti-VEGF drug, like bevacizumab, would only contribute a \(<5\%\) decrease in VEGFR2 ligation when cross-family binding is considered in breast cancer xenograft-derived endothelial cells (Fig. 10A). Therefore, we predict that cross-family interactions may allow VEGFR2 complex formation to remain relatively unchanged when bevacizumab is administered, despite the fact that PDGFs bind VEGFR2 with affinities \(<2\) orders of magnitude weaker than VEGF-A (Fig. 10A).

The increased VEGFR2 ligation that we predict under a cross-family paradigm is attributed to the 10–100-fold higher PDGF to VEGF concentrations in serum under healthy physiological conditions. Indeed, we have included...
a meta-analysis comparing serum concentrations of VEGF-A and PDGFs across healthy and pathological conditions to contextualize these differences (Fig. 11). Such high PDGF concentrations may subsequently enable PDGFs to account for up to ~96% of VEGFR2 ligation under healthy conditions (Fig. 10B). Similarly, breast cancer patient serum is measured to have 25-to-40-fold higher PDGF levels than VEGF (Fig. 10A), so when considering VEGF-A and PDGFs, we predict up to 90% steady state ligation by PDGFs in breast cancer and nearly 100% ligation by PDGFs under conditions of anti-VEGF therapy (Fig. 10B). Our model suggests that this buffering of angiogenic signaling during anti-VEGF therapy may be mediated as follows: PDGF-AB > PDGF-AA > PDGF-BB > VEGF-A (Fig. 10B).

As previously described, we do not include PDGF-CC in the model given its limited expression pattern (e.g., ischemic event) [51]. However, we expect that PDGF-CC:VEGFR2 will dominate VEGFR2 ligation following ischemic damage for two reasons: (1) after ischemic injury PDGF-CC has a 150–300 fold greater serum concentration than VEGF-A (Fig. 11), and (2) PDGF-CC has similar, high-affinity (~100 pM) VEGFR2 binding as canonical VEGF-A:VEGFR2. Furthermore, we predict that PDGF-CC:VEGFR2 ligation would dominate whenever PDGF-CC serum concentrations are 2-fold greater than VEGF-A. We can extend a similar analysis to the other PDGF ligands. Our meta-analysis of PDGF and VEGF serum concentrations would also suggest that in every case where any PDGF serum concentration is at least 25-fold greater than VEGF, then PDGF:VEGFR2 ligation should significantly modulate VEGFR2 signaling. This would include in cancer, post-stroke, and during exercise (Fig. 11).
Discussion

In this study, we established a \( \chi^2 \)-to-\( R_{\text{max}} \) cut-off (where values are < 1.0) for distinguishing non-binding and binding interactions, which we used in the discovery of new PDGF-VEGFR interactions: (1) PDGF-AA to VEGFR2, (2) PDGF-AB to VEGFR2, (3) PDGF-BB to VEGFR2, and (4) PDGF-CC to VEGFR2 (summarized in Fig. 7). We measured both the kinetics of these new interactions; and for the first time, we measured the kinetics for VEGF-A:PDGFR binding. In a cross-family signaling system, where several ligands compete to bind with the same receptor, the ligand concentrations and ligand-receptor binding kinetics determine which ligand(s) dominate signaling. Therefore, our computational analysis provided quantitative evidence that PDGF:VEGFR2, cross-family binding should significantly participate in VEGFR2 ligation under conditions of health physiology, breast cancer, and pathologies where PDGFs significantly outnumber VEGFs. Furthermore, our modeling offers predictions on how PDGF:VEGFR2 interactions may sustain VEGFR2 ligation when VEGF-A is inhibited (e.g., bevacizumab, ziv-aflibercept). Together these findings offer new insight into several fields of research, including anti-angiogenic drug development and cancer, which we contextualize herein.

Cross-family interactions may shed new light on anti-angiogenic drug development.

Our discovery of cross-family interactions can advance anti-angiogenic drug development, which is currently guided by a uni-family view. Anti-VEGF success has been limited, due to both intrinsic resistance and acquired resistance (relapse). Several mechanisms have been proposed to explain anti-VEGF resistance, a few include: (1) Increased mural cells: some tumors resist anti-angiogenic drug treatment via increased pericyte coverage of tumor vessels, providing a permeability barrier to anti-VEGF therapy. (2) Increased tumor invasiveness: tumor undergoes enhanced metastasis into healthy tissue as a means of co-opting existing vasculature, thereby seeking to avoid hypoxia or nutrient deprivation and bypassing anti-VEGF therapy. (3) Ancillary growth factors: some tumors secrete additional growth factors, such as PDGFs and fibroblast growth factors, which enable ancillary angiogenic signaling axes to bypass anti-VEGF therapy. The latter mechanism may be supported by our findings if PDGF:VEGFR2 complexes lead to VEGFR2 activation and angiogenic signaling. Therefore, future work should determine how PDGF:VEGFR2 ligation regulates native VEGFR2 signaling.

Cross-family signaling may also aid our understanding of multi-target small molecule inhibitors, like sorafenib and sunitinib. Sorafenib inhibits VEGFR2, VEGFR3 and PDGFR, while sunitinib inhibits PDGFR and all VEGFRs. When viewed through the uni-family signaling lens, these small molecules would only inhibit uni-family interactions, i.e. blocking PDGFR autophosphorylation would render PDGF ligands as non-functional. This perspective does not explain why patients also relapse on these cross-family anti-angiogenic drugs. Under a cross-family paradigm, blocking VEGFR and PDGFR would shift VEGF and PDGF binding to receptors of other signaling families. Some possibilities could be other, structurally similar tyrosine kinase receptors with angiogenic function, such as: nerve, fibroblast, and transforming growth factor receptors. Our work suggests that drug resistance to multi-target therapeutics can be better informed and overcome by identifying the extent of cross-family binding.

The tip of the iceberg? Structural analysis can guide further cross-family discovery.

Our results open the possibility that that other cross-family interactions exist, but remain undiscovered. Experimentally screening for interactions between every known cytokine with every known receptor would be cost- and time-prohibitive. Instead, structural analysis of shared ligand and receptor structural motifs can guide further discovery. For example, VEGFRs and PDGFRs are tyrosine kinase receptors: PDGFRs have 5 extracellular immunoglobulin-like (IgG-like) domains and VEGFRs have 7 extracellular IgG-like domains in VEGFRs. Of these, domains 2–3 are responsible for high-affinity binding of VEGF-A:VEGFR1 and VEGF-A:VEGFR2.
Domains 2–3 are highly-conserved within PDGFRs, where they play an identical role of housing the PDGF binding site. The common ligand-binding domains suggest that PDGFs could utilize these sites to bind VEGFs. Moreover, VEGF and PDGF are similar in quaternary structure: VEGF and PDGF have only a 1.93 Å root mean square difference between overlapping structures66 (Fig. 1B). VEGFs and PDGFs also share structural motifs in their receptor-binding regions64. In fact, PDGF ligands have been superimposed within the VEGF-A:VEGFR2 binding domains, illuminating the possible confirmations for the interactions we report99. Additionally, VEGFRs and PDGFRs have a similar intracellular structure: having an intracellular split tyrosine-kinase domain67,68. Such a feature may lend the possibility of agonist or partial agonist action via cross-family binding.

Cysteine knot ligands66,69 with some of these VEGF-PDGFR structural properties should also be investigated: these include: nerve growth factors, fibroblast growth factors, transforming growth factors, and even glycoprotein hormones, due to their structural similarity to PDGF66. Examining other receptors that exhibit multi-ligand binding would offer a good template for understanding the possibilities in cross-family binding. For example, early work by Pennock et al. explored whether VEGF-A served as a cross-family agonist or antagonist for the PDGF receptors, finding the ligand acted antagonistically70. Outside the VEGFs and PDGFs, the nicotinic acetylcholine receptor is well known for having several possibilities for receptor assembly, and several molecules, other than nicotine that can bind with agonist-partial agonist-antagonist affect (e.g., epibatidine, choline, etc.)71. The transforming growth factor-β superfamily also offers a good template to examine multi-binding interactions, where extensive cross-family ligandreceptor binding between the subgroups, transforming growth factor-β3, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and the activin/inhibins72 are responsible for maintaining a complicated regulatory network73. Structural analysis, therefore, can enable a focused screening of likely cross-family binding partners.

Computational modeling will drive conceptual understanding of cross-family signaling. Computational modeling has provided new insight into the uni-family activation of several growth factor-receptor families, including EGF74, FGF75, PDGF76, and VEGF5,50,57-59. Here, our PDGF—VEGFR2 modeling and analysis predicted conditions where PDGF—VEGFR2 binding prevails, which included normal physiological conditions. While we do find the high-affinity of these cross-family interactions surprising, we do not find the modeling results to be surprising. It follows that when incorporating a new population of ligands—at concentrations higher than VEGF-A, and which bind the same receptor at affinities either slightly lower or similar to VEGF-A—the receptor would be substantially ligated by these new ligands. We expect that these patterns of ligated-receptor dominance could change when different healthy biological conditions are considered, such as when receptor trafficking rates are altered by changes in blood flowrate-induced shear stresses82. As we continue exploring this new paradigm, additional models will need to determine how cross-family receptor occupancy translates to various receptor activation landscapes. An elegant computational framework for examining the possible receptor landscapes is the recent work on how bone morphogenetic proteins (BMP) and their receptors achieve multiple activation profiles83. We expect that further computational modeling of cross-family signaling will enable a similar understanding of receptor activation landscapes (full-agonist, partial-agonist, partial antagonist, and full-antagonist), receptor activation dynamics (fast/burst, slow/sustained, etc.), and effector efficiencies.

Another computational approach that should be enlisted for understanding maximal canonical signaling is the recent “meta-model” from our laboratory, which modeled receptor activation across eight, canonical ligand-receptor pairs84. This meta-model offered ranked predictions of receptor signaling, based on the integrated receptor activation response: PDGFR3 >IGFR1 >EGFR >PDGFRα >VEGFR1 >VEGFR2 >Tie2 >FGR1. Because these receptors activate similar second messengers, this ranking of canonical (uni-axis) signaling provided the first guide for manipulating signaling in cells carrying combinations of these receptors. We envision that a multi-family model that incorporates the foundational model we present here, signaling landscapes83, and growth factor receptor hierarchy84 will offer novel predictions for maximally tuning signaling. Furthermore, we will test more conditions than are accessible by experiment to understand the multiple cross-family signaling permutations.

Future studies: Filtering novel interactions via the \( \chi^2 \)-to-\( R_{\text{max}} \) heuristic. Once structural analysis predicts additional cross-family partners, validation can use a similar SPR approach, as we established here. Towards such goals, researchers may apply the \( \chi^2 \)-to-\( R_{\text{max}} \) ratio that we discuss to designate “true” interactions from non-specific, non-1:1 Langmuir interactions. Indeed, SPR can often produce large response curves that suggest binding, even where no interaction exists. Such curves are primarily due to two types of non-specific binding: (1) sensor-ligand interactions85 and (2) receptor-ligand interactions86. The former can be corrected by coating a flow cell with a non-binding reference protein. Without the use of a reference protein, non-specific effects would artificially inflate the observed binding affinity strength (lower \( K_a \)). For this study we used angiopoietin-4 as a reference (see Materials and Methods); thus minimizing non-specific interactions between ligand and chip. However, previous SPR measurements of PDGF-PDGFR interactions, did not use a reference protein45. We believe this critical difference explains our different affinities, with prior studies measuring a weaker binding affinity. Non-specific ligand-receptor interactions can also be accounted for when you consider that such interactions would not likely follow a 1:1 Langmuir binding model. This is due to the fact that many non-specific interactions are mediated by transient electrostatic attractions between amino acid residues on the ligand and receptor. These transiently-interacting residues can be distributed throughout both proteins—are therefore not site-specific—and should not follow a 1:1 interaction pattern44-48 indicated by the \( \chi^2 \)-to-\( R_{\text{max}} \) ratio. Future measurements of cross-family binding should apply our finding that \( \chi^2 \)-to-\( R_{\text{max}} \) ratio >1.0 is attributed to non-specific binding.
Conclusion

These studies offer new interpretations of tyrosine kinase receptor signaling: a cross-family paradigm. We provide standards for kinetic analyses of novel interactions with broad implications for tyrosine kinase receptor signaling. Through computational modeling, we further predict that cross-family interactions may significantly alter signaling. From these results, we propose a new mechanism for anti-angiogenic drug resistance, which may aid drug development.

In addition to the applications of this work for tumor angiogenesis, PDGF-VEGF cross-family signaling should affect our understanding of cardiovascular-dependent diseases, governed by angiogenic signaling, including: wound healing, exercise, and other cardiovascular pathologies. Moreover, it should enable improved vascularization in the areas of tissue engineering and regenerative medicine.

Finally, our work suggests that structural similarities in signaling ligands and receptors could indicate cross-family binding patterns and that this phenomenon could be common across cell signaling (e.g., agonist/ partial agonist paradigm). These and any new interactions can and should be illuminated through structural analysis and computational modeling.

Materials and Methods

Surface plasmon resonance (SPR).

All SPR studies were performed with the BIAcore 3000 instrument (Biacore International AB, Uppsala, Sweden) at 25°C on dextran-coated gold sensor chips (CM5, Research grade, GE Healthcare Bio-sciences AB, Uppsala). The BIAcore 3000 divides CM5 sensor chips into four separate flow cells. We immobilized a different receptor protein in each flow cell: The first cell was reserved for measuring non-specific binding by immobilizing recombinant angiopoietin-4 (Cat. #964-AN-025/CF, R&D Systems) to a flow cell: it has no known interaction with VEGFs or PDGFs. Three different receptors were immobilized to the three remaining flow cells. Running buffer: 1x HBS-EP pH 7.4 (10 mM HEPES, 3 mM EDTA, 150 mM NaCl, 0.005% TWEEN-20, cat. # BR100188, GE Life Sciences).

Optimizing immobilization conditions.

Human recombinant VEGFR1 (Cat. #321-FL-050/CF, R&D Systems), VEGFR2 (Cat. #357-KD-050/CF, R&D Systems), VEGFR3 (Cat. #349-F4-050, R&D Systems), PDGFRα (Cat #322-PR-050/CF, R&D Systems) and PDGFRβ (Cat. #385-PR-100/CF, R&D Systems) were immobilized on flow cells by first performing pre-concentration studies to determine optimal receptor-immobilization pH (Supplementary Table S6), as follows: 20 µg/mL receptor + 10 mM acetate buffers ranging from pH 3.5 to 0.5–1.0 below the protein isoelectric point (Supplementary Table S6) were prepared. Known receptor-ligand binding was introduced at 5 µl/min (association), followed by 5-µl injection of ethanolamine-HCL (GE Healthcare AB, Uppsala, Sweden) to clear the surface. We selected the optimal acetate buffer pH for each protein based on (1) the maximum level of protein immobilization reached and (2) the rate of immobilization observed in the pre-concentration study sensograms.

Protein immobilization.

Receptor proteins were immobilized to the sensor dextran matrix via amine coupling. Flow cells were activated by injecting 35 µL of a 1:1 volumetric mixture of 0.05 M NHS (N-hydroxysuccinimide) and 0.2 M EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) at 5 µL/min. 20 µg/mL of the aforementioned recombinant receptor in 10 mM acetate buffer at its optimal pH was injected at 5 µL/min until the target level was reached (approximately 200–500 R.U. of immobilized receptor). After sufficient protein coupling (~200–500 R.U. immobilized protein), the surface was de-activated by 35 µL ethanolamine (ethanolamine hydrochloride-NaOH pH 8.5, GE Healthcare AB) (Supplementary Fig. S2).

Ligand-receptor association and dissociation kinetics.

Fresh ligand solutions were prepared at 40, 20 and 10 nM in HBS-EP running buffer each experimental day, including: human recombinant VEGFA (R&D Systems, Cat. #293-VE-010), PDGF-AA (Cat. #222-1A-050), -AB (Cat. #222-AB-050), -BB (Cat. #220-BB-050), -CG (Cat. #1687-CC-025) and -DD (Cat. #1159-SB-025) (Note: All ligands were obtained from R&D Systems, Cat. #293-VE-010), PDGF-AA (Cat. #221-AA-050), -AB (Cat. #222-AB-050), -BB (Cat. #220-BB-050), -CG (Cat. #1687-CC-025) and -DD (Cat. #1159-SB-025). After sufficient protein coupling (~200–500 R.U. immobilized protein), the surface was de-activated by 35 µL ethanolamine (ethanolamine hydrochloride-NaOH pH 8.5, GE Healthcare AB) (Supplementary Fig. S2).

Kinetic analysis.

The raw ligand:receptor sensograms were aligned and the background, non-specific binding was subtracted using the sensogram trace from the ligand:Ang-4 flow cell (Supplementary Figure S3). Both the raw ligand:receptor and ligand:Ang-4 sensogram curves were obtained within the BIAcore 3000’s detection window (10–70,000 R.U.) for all interactions to ensure detected interactions did not represent system noise. Post-subtraction sensograms with a negative-sloped association phase were excluded from global kinetic fitting and not considered interactions. BIAevaluation removes momentary signal spikes resulting from transient air bubbles.

Global analysis is considered to produce more accurate results than fitting of a single response curve, so global fitting was performed with BIAevaluation software (Version 4.1.1, GE Healthcare), which follows 1:1 Langmuir adsorption isotherm (Equation 1). The software applies nonlinear least squares analysis to determine association (kₐ) and dissociation (k₆) rates fitting best to multiple response curves simultaneously. Additionally, the software provides the goodness-of-fit parameter χ² and the peak magnitude of the signal response, Rₘₐₓ:

\[ R + L \xrightarrow{k_a} RL \xrightarrow{k_d} R + L \]

(1)
Classifying binding. Both the instrument manufacturer (BIAcore) and previous researchers have suggested that when fitting kinetic rate constants using global analysis, a $\chi^2$-to-$R_{\text{max}}$ value (a measure of noise-to-signal) $< 0.2$ is ideal for confidence in the kinetic parameters obtained when studying known interactions. A $< 0.2$ noise-to-signal indicates that the sensogram signal includes minimal contributions from the following three noise-factors: (1) overall instrument noise, (2) heterogeneities in immobilized receptor or ligand, and (3) non-specific interactions. Using ligand:receptor pairs with known interactions and pairs known not to interact, we established a cut-off value of $\chi^2$-to-$R_{\text{max}} < 1.0$ that differentiates real, 1:1 Langmuir interactions, from predominantly non-specific interactions, where $\chi^2$-to-$R_{\text{max}} > 1.0$. We arrived at this via experimentally fitting known interactions and non-interactions (Supplementary Table S1). We then applied the $\chi^2$-to-$R_{\text{max}} < 1.0$ heuristic to classify the interactions observed in PDGF-VEGF binding.

Single-cell model of membrane receptor activation. We recapitulated the uni-family (VEGF:VEGFR) single cell model described by Mac Gabhann et al., consisting of 7 ordinary differential equations (ODEs) derived using the law of mass action. The cell is represented as a single compartment that represents both the extracellular space and plasma membrane. We extended this to a dual-family model, including the 7 ODEs describing VEGF:VEGFR ligation plus an additional 8 ODEs describing PDGF:VEGFR2 signaling. The model equations and parameters are implemented in MATLAB using the Simbiology toolbox. Steady-state and dynamic solutions are computed using the ode15 solver for 24 simulated hours. A complete description of model equations for both uni-family and dual-family models are provided in Supplementary Text 1.

Model parameters. Parameters are based upon 7 guidelines. (1) VEGFR1 and VEGFR2 are inserted into the plasma membranes at fixed rates. (2) Ligand-free receptors and ligand-bound receptors are internalized from the plasma membrane at fixed rates (see Supplementary Table S4 for full summary of kinetic parameters). (3) VEGFR dimerization is not modeled explicitly, reflecting recent work that suggests VEGFR receptors are initially pre-dimerized, and ligand-binding initiates a conformational change that enables phosphorylation and down-stream signaling events. (4) Ligand secretion and ligand clearance are not modeled to better represent a localized cell environment without the influence of the systemic dynamics. (5) Ligand concentrations are derived from known serum concentrations (Supplementary Table S5). (6) Benchmark kinetic and concentration parameters are used only to recapitulate the benchmark. (7) The cross-family model applied updated kinetic parameters via SPR studies herein, (Supplementary Table S2) and updated VEGFR concentrations, which were based on recent quantitative flow (qFlow) cytometry measurements. All model parameters, their descriptions, and their values are provided in Supplementary Table S4.

We modeled anti-angiogenic drug treatment by incorporating the anti-VEGF-A antibody, bevacizumab. In the model, bevacizumab reversibly binds free VEGF-A, with kinetic constants previously-determined via SPR. Drug treatment was modeled as a single, initial bevacizumab dose. The dose concentration used was adopted from an earlier VEGF computational model that based the dosage on patient plasma concentrations following the administration of bevacizumab in advanced cancer treatment. Thus, this value correlates with the systemic level of bevacizumab. We excluded bevacizumab clearance and ‘secretion’ (the movement of bevacizumab from plasma into the area around endothelial cells), to examine the concentrations individual endothelial cells would experience.

Data availability Statement. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 17, 611–625 (2016).
2. Chang, C. C. et al. Angiogenesis in a microvascular construct for transplantation depends on the method of chamber circulation. Tissue engineering. Part A 16, 795–805 (2010).
3. Mac Gabhann, F., Qutub, A. A., Annex, B. H. & Popel, A. S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2, 794–707 (2010).
4. Mac Gabhann, F., Annex, B. H. & Popel, A. S. Gene therapy from the perspective of systems biology. Current opinion in molecular therapeutics 12, 570–577 (2010).
5. Gupta, R., Tongers, J. J. & Losordo, D. W. Human studies of angiogenic gene therapy. Circulation Research 105, 724–736 (2009).
6. Annex, B. H. Therapeutic angiogenesis for critical limb ischemia. Nat Rev Cardiol 10, 387–396 (2013).
7. Sedighiani, F. & Nikol, S. Gene therapy in vascular disease. Surgeon 9, 326–335 (2011).
8. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Reviews. Cancer 3, 401–410 (2003).
9. Erber, R. et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 18, 338–340 (2004).
10. Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005).
11. Attanasio, S. & Snell, J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiology in review 17, 115–20 (2009).
12. Hsu, C. W. et al. Improved angiogenesis in response to localized delivery of macrophage-recruiting molecules. PLoS ONE 10, 1–27 (2015).
13. Shah, N. J. et al. Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction. Proceedings of the National Academy of Sciences of the United States of America 1–6, https://doi.org/10.1073/pnas.1408035111 (2014).
14. Finley, S. D. & Popel, A. S. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. The AAPS journal 14, 500–9 (2012).
15. Koch, S., Tugues, S., Li, X., Gualandi, L. & Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 437, 169–183 (2011).
16. Ladomery, M. R., Harper, S. J. & Bates, D. O. Alternative splicing in angiogenesis: The vascular endothelial growth factor pathway. Cancer Letters 249, 133–142 (2007).

17. Biselli-Chicote, P. M., Oliveira, A. R. C. P., Pavarino, E. C. & Goloni-Bertolino, E. M. VEGF gene alternative splicing: pro-and anti-angiogenic isoforms in cancer. Journal of Cancer Research and Clinical Oncology 138, 363–370 (2012).

18. Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer research 62, 4123–31 (2002).

19. Konopatskaya, O., Churchill, A. J., Harper, S. J., Bates, D. O. & Gardiner, T. A. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Molecular vision 12, 626–632 (2006).

20. Chappell, J. C. et al. Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation. Cardiovascular Research 111(4), LP-93 (2016).

21. Carmeliet, P. & Collen, D. Vascular development and disorders: Molecular analysis and pathogenic insights. Kidney Int 53, 1519–1549 (1998).

22. Betsholtz, C., Karlsson, L. & Lindahl, P. Developmental roles of platelet-derived growth factors. BioEssays 23, 494–507 (2001).

23. Battegay, E. J., Rupp, I., Iruela-Arispe, L., Sage, E. H. & Pech, M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. The Journal of cell biology 125, 917–928 (1994).

24. Brown, D. M., Hong, S. F., Farrell, C. L., Pierce, G. F. & Khouri, R. K. Platelet-derived growth factor BB induces functional vascular anastomoses in vivo. Proceedings of the National Academy of Sciences 92, 5989–5994 (1995).

25. Lindner, V. & Reid, M. A. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. The American journal of pathology 146, 1488 (1995).

26. Martins, R. N., Chleboun, J. O., Sellers, P., Sleigh, M. & Muir, J. The Role of PDGF-BB on the Development of the Collateral Circulation after Acute Arterial Occlusion. Growth Factors 10, 299–306 (1994).

27. Ball, S. G., Shuttleworth, C. A. & Kielty, C. M. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. The Journal of Cell Biology 177, 489–500 (2007).

28. Reigstad, L. J. et al. Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure. The Journal of biological chemistry 278, 17114–1720 (2003).

29. Muller, Y. A., Christinger, H. W., Keyt, B. A. & de Vos, A. M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.9 A resolution: multiple copy flexibility and receptor binding. Structure (London, England) 1993:5, 1325–1338 (1997).

30. Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809–813 (2008).

31. Greenberg, J. I. & Cheshier, D. A. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opinion on Biological Therapy 9, 1347–1356 (2009).

32. Ball, S. G., Shuttleworth, C. A. & Kielty, C. M. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. The Journal of Cell Biology 177, 489–500 (2007).

33. Majesky, M. W. Developmental basis of vascular smooth muscle diversity. Arteriosclerosis, Thrombosis, and Vascular Biology 27, 1248–1258 (2007).

34. Karlsson, R. Affinity analysis of non-steady-state data obtained under mass transport limited conditions using BIAcore technology. Journal of molecular recognition: JMR 12, 285–292 (1999).

35. Murphy, M., Jason-Moller, L. & Bruno, J. Using Biacore to measure the binding kinetics of an antibody-antigen interaction. Current protocols in protein science editorial board John E Coligan et al Chapter 19, Unit 19.14–Unit19.14 (2006).

36. Biacore, A. B., July, E. & Biacore, A. B. BIAevaluation Software Handbook. System (Biacore AB, 1997).

37. Nilsson, I. et al. VEGF receptor 2/3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 29, 1377–1388 (2010).

38. Seifert, R. A. et al. Two different subunits associate to create isomorph-specific platelet-derived growth factor receptors. Journal of Biological Chemistry 264, 8771–8778 (1989).

39. von Tiedemann, B. & Bilitewski, U. Characterization of the vascular endothelial growth factor receptor interaction and determination of the recombinant protein by an optical receptor sensor. Biosensors and Bioelectronics 17, 983–991 (2002).

40. Cunningham, S. A., Tran, T. M., Arrate, M. P. & Brock, T. A. Characterization of Vascular Endothelial Cell Growth Factor Interactions with the Kinase Insert Domain-containing. The Journal of biological chemistry 274, 18421–18427 (2000).

41. Hart, C. E. et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240, 1529–1531 (1988).

42. Fleming, T. P., Matsu, T. & Aaronson, S. A. Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Experimental gerontology 27, 523–532 (1992).

43. Fretto, L. J., J. J. et al. Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor. Journal of Biological Chemistry 268, 3625–3631 (1993).

44. Moriya, J. et al. Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice. Journal of Vascular Surgery 59, 1402–1409.e4 (2014).

45. Lin, X., Takahashi, K., Liu, Y., Derrien, A. & Zamora, P. O. A synthetic, bioactive PDGF mimetic with binding to both alpha-PDGF and beta-PDGF receptors. Growth factors (Chur, Switzerland) 25, 87–93 (2007).

46. Klipp, E., Liebermeister, W., Wierling, C., Kowald, A. & Herwig, R. Systems Biology: A textbook. (Wiley-Blackwell, 2016).

47. Horn, F. & Jackson, R. General mass action kinetics. Archive for Rational Mechanics and Analysis 47, 81–116 (1972).

48. Janes, K. A. & Lauffenburger, D. A. A biological approach to computational models of proteomic networks. Current Opinion in Chemical Biology 10, 73–80 (2006).

49. Lauffenburger, D. A & Linderman, J. A. Receptors: Models for binding, trafficking and signaling. 40 (Oxford University Press, 1994).

50. Rodríguez-Gonzalez, R. et al. Platelet derived growth factor–CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator. Atherosclerosis 226, 165–171 (2013).

51. Morris, A. & Lam, K. N. Bryant, P. & Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. The Journal of Biological Chemistry 276, 9289–98 (2001).

52. Berghuis, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592–603 (2008).

53. Jain, R. K. & Booth, M. F. What brings pericytes to tumor vessels? Journal of Clinical Investigation 112, 1134–1136 (2003).

54. Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (New York, NY) 2, 306–314 (2000).

55. Christensen, J. G. A preclinical review of sintilimab, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Annals of Oncology 18, 3–10 (2007).

56. Cantarella, G. et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 1307–1309 (2002).
60. Lieu, C., Heymach, J., Overman, M., Tran, H. & Kopetz, S. Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. *Clinical Cancer Research* **17**, 6130–6139 (2011).

61. Roberts, A. B. *et al.* Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proceedings of the National Academy of Sciences* **83**, 4167–4171 (1986).

62. Kovalenko, M. V. M., Kazlauskas, A., William, J. L. & Lane, M. D. Platelet-Derived Growth Factor Receptor Family. *Encyclopedia of Biological Chemistry* **3**, 399–406 (2004).

63. Starovasnik, M. A. *et al.* Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states. *Journal of molecular biology* **293**, 531–544 (1999).

64. Wiesmann, C. *et al.* Crystal structure at 1.7 Å of Flt-1 in complex with domain 2 of the Flt-1 receptor. *Cell* **91**, 695–704 (1997).

65. Fuh, G., Li, R., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. *Journal of Biological Chemistry* **273**, 11197–11200 (1998).

66. Muller, Y. A. *et al.* Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. *Proceedings of the National Academy of Sciences of the United States of America* **94**, 7192–7197 (1997).

67. McGuire, M. A. *et al.* Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. *Structure (London, England)* **3**, 319–330 (1995).

68. Chen, P. P. H., Chen, X. & He, X. Platelet-derived growth factors and their receptors: Structural and functional perspectives. *Biochimica et Biophysica Acta (BBA)–Proteins* **1834**, 2176–86 (2012).

69. Iyer, S. & Acharya, K. R. Tying the knot: The cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. *FEBS Journal* **278**, 4304–4322 (2011).

70. Pennock, S. & Kazlauskas, A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. *Molecular and cellular biology* **32**, 1955–1966 (2012).

71. Drenan, R. M. *et al.* Subcellular Trafficking, Pentameric Assembly, and Subunit Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors Containing Fluorescently Labeled a6 and b3 Subunits. *Molecular pharmacology* **73**, 27–41 (2008).

72. Yadlin, D., Knaus, P. & Mueller, T. D. Structural insights into BMP receptors: Specificity, activation and inhibition. *Cytokine and Growth Factor Reviews* **27**, 13–34 (2016).

73. Nicklas, D. & Saiz, L. Computational modelling of Smad-mediated negative feedback and crosstalk in the TGF-β superfamily network. *Journal of the Royal Society, Interface/the Royal Society* **10**, 20130363 (2013).

74. Wiley, H. S. *et al.* Computational modeling of the EGF-receptor system: a paradigm for systems biology. *Trends in Cell Biology* **13**, 43–50 (2003).

75. Filon, R. I. & Popel, A. S. A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. *Annals of Biomedical Engineering* **32**, 645–663 (2004).

76. Park, C. S., Schneider, I. C. & Haugh, J. M. Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. *Journal of Biological Chemistry* **278**, 37064–37072 (2003).

77. Qutub, A. A. *et al.* Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. *RMC Syst Biol* **3**, 13 (2009).

78. Ji, J. W., Mac Gabhann, F. & Popel, A. S. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. *American journal of physiology. Heart and circulatory physiology* **293**, H3740–H3749 (2007).

79. Mac Gabhann, F., Ji, J. W. & Popel, A. S. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. *J Appl Physiol (1985)* **102**, 722–734 (2007).

80. Vempati, P., Mac Gabhann, F. & Popel, A. S. Quantifying the Proteolytic Release of Extracellular Matrix-Quenched VEGF with a Computational Model. *PLoS ONE* **5**, e11860 (2010).

81. Qutub, A., Gabbann, F., Karagiannis, E., Vempati, P. & Popel, A. Multiscale models of angiogenesis. in *IEEE Engineering in Medicine and Biology Magazine* **28**, 14–31 (2009).

82. Chen, K. *et al.* Mechanotransduction in Response to Shear Stress. *The Journal of biological chemistry* **274**, 18393–18400 (1999).

83. Anteby, Y. E. *et al.* Combinatorial Signal Perception in the BMP Pathway. *Cell** 170**, 1184–1196 e24 (2017).

84. Weddel, J. C. & Imoukhuede, P. I. Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling. *Integrative Biology* (2017). https://doi.org/10.1039/C7IB00011A

85. Fong, C. C., Wong, M. S., Fong, W. F. & Yang, M. Effect of hydrogel matrix on binding kinetics of protein-protein interactions on sensor surface. *Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex.*

86. Haseley, S. R., Talaga, P., Kamerling, J. P. & Vliegenthart, J. F. Characterization of the carbohydrate binding specificity and kinetic parameters of lectins by using surface plasmon resonance. *Analytical biochemistry* **274**, 203–210 (1999).

87. Drake, A. W. *et al.* Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. *Analytical Biochemistry* **429**, 58–69 (2012).

88. Fiwash, M., Towler, E. M. & Fisher, R. J. BiAcore for macromolecular interaction. *Current Opinion in Biotechnology* **9**, 97–101 (1998).

89. Huntsman, H. D. *et al.* Mesenchymal stem cells contribute to vascular growth in skeletal muscle in response to eccentric exercise. *American journal of physiology. Heart and circulatory physiology* **304**, H72–H81 (2013).

90. Hirsch, A. T. *et al.* Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. *JAMA: The Journal of the American Medical Association* **286**, 1317–24 (2001).

91. Peng, E., Spray, D. C. & Tarbell, J. M. The Glypican-1 HS Core Protein of the Glycocalyx is Important for Flow-induced Endothelial NOS Activation but not Cell Remodeling. *The FASEB Journal* **25**(39), 39–99.9 (2011).

92. Ordedin-McCoy, O. *et al.* Novel factor-loaded polyphosphazene matrices: potential for driving angiogenesis. *Journal of microencapsulation* **26**, 544–55 (2009).

93. Pence, J. C., Clancy, K. B. H. & Harley, B. A. The induction of pro-angiogenic processes within a collagen scaffold via exogenous estradiol and endometrial epithelial cells. *Biotechnology and Bioengineering* **112**, 2185–2194 (2015).

94. GE Healthcare Life Sciences. Biacore Assay Handbook. *GE Healthcare Bio-Sciences AB* 1–78 (2012).

95. Roden, L. D. & Myszka, D. G. Global analysis of a macromolecular interaction measured on BiAcore. *Biochemical and biophysical research communications* **225**, 1073–1077 (1996).

96. Karlsson, R. & Falt, A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. *Journal of immunological methods* **200**, 121–133 (1997).

97. Burke, P., Schooeler, K. & Wiley, H. S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. *Molecular biology of the cell* **12**, 1897–1910 (2001).

98. Sarabipour, S., Ballmer-Hofer, K. & Hristova, K. VEGFR-2 conformational switch in response to ligand binding. *elsie* **5**, 1–23 (2016).

99. Chen, S., Guo, X., Imaremez, O. & Imoukhuede, P. I. Quantification of VEGFReceptors, NRPI, and PDGFRs on Endothelial Cells and Fibroblasts Reveals Serum, Intra-Family Ligand, and Cross-Family Ligand/Regulation. *Cellular and Molecular Bioengineering* **8**, 383–403 (2015).

100. Imoukhuede, P. I. & Popel, A. S. A. S. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. *Experimental Cell Research* **317**, 955–965 (2011).
101. Imoukhuede, P. I. & Popel, A. S. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer medicine 3, 225–244 (2014).
102. Chen, S. et al. In Biomedical Nanotechnology: Methods and Protocols (eds. Petrosko, S. H. & Day, E. S.)117–138 (Springer New York, 2017). https://doi.org/10.1007/978-1-4939-6840-4_8.
103. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185 (2012).
104. Finley, S. D., Chu, L.-H. & Popel, A. S. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today 0, (2014).
105. Stefanini, M. O., Wu, F. T. H., Mac Gabhann, F. & Popel, A. S. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Research 70, 9886–9894 (2010).

Acknowledgements
We would like to thank Dr. Brian Imai for his assistance and advice operating the BIAcore 3000 instrument. This work was supported by American Heart Association (Grant #16SDG26940002), the American Cancer Society, Illinois Division (Grant #282802), the National Science Foundation (NSF Grant #1743333, NSF #1743334, NSF #1640783, NSF CAREER Award #1653925, NSF CBET #1512598, and NSF BPE #1648454), and the National Science Foundation Cellular and Molecular Mechanics and BioNanotechnology Integrative Graduate Education and Research Traineeship.

Author Contributions
S.B.M., J.W., M.K., and P.I.I. conceived the experiments; S.B.M., A.P., and A.W. conducted the experiments; S.B.M. and P.I.I. analyzed the results; S.B.M, A.P., and A.W. prepared the figures and tables; and S.B.M., S.C., J.W., A.P., A.W., and P.I.I. contributed to the writing of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16610-z.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017